


Red flags potentially suggestive of ATTR amyloidosis

ATTR amyloidosis is a systemic, progressive, and potentially fatal disease caused by misfolded transthyretin protein forming amyloid deposits in organs and nerves.¹⁻³

Overlapping signs and symptoms with other conditions may lead to frequent misdiagnoses or delayed diagnosis.^{1,2,4,5}


Suspect ATTR amyloidosis when unexplained symptoms occur with ≥1 of the following red flags or mimickers:⁶⁻⁹



If ATTR amyloidosis is suspected, consider referral to the National Amyloidosis Centre (NAC) for specialist evaluation.^{10,11}

The NAC is the national centre of excellence for amyloidosis care, providing specialist care and research nationally.* It provides comprehensive diagnostic evaluation, genetic testing, management recommendations and long-term follow-up.¹⁰

The NAC patient pathway^{10,11}



The UK Amyloidosis Network (UKAN) is expanding access to specialist services through new regional centres in Birmingham (the Midlands Amyloidosis Service [MAS]) and Liverpool (coming soon). These centres will work in close collaboration with the NAC to provide more localised diagnostic services and multidisciplinary expertise.

How to refer to specialist amyloidosis services



Send referral letters to:

National Amyloidosis Centre
Royal Free Hospital NHS Foundation Trust
Pond Street
London, NW3 2QG
Email: rf-tr.amyloidosis-admin@nhs.net
Tel: 0207 433 2800
Letters addressed to a listed consultant



Scan the QR code to visit the NAC website
(third-party site; AstraZeneca is not responsible for its content)



Scan the QR code to find out more about the signs and symptoms of ATTR amyloidosis on the AstraZeneca See the pATTRns website

*The NAC is commissioned by NHS National Specialised Services and funded by the Department of Health.^{10,11}

ATTR=transthyretin amyloidosis; CIPD=chronic inflammatory demyelinating polyneuropathy; CTS=carpal tunnel syndrome; GI=gastrointestinal; HCP=healthcare professional; MAS=Midlands Amyloidosis Service; MDT=multidisciplinary team; NAC=National Amyloidosis Centre; NHS=National Health Service; UKAN=UK Amyloidosis Network.

1. Nativi-Nicolau JN, et al. *Heart Fail Rev.* 2022;27:785–793; 2. Gertz M, et al. *BMC Fam Pract.* 2020;21(1):198; 3. Ioannou A, et al. *BioDrugs.* 2023;37:127–142; 4. Rozenbaum MH, et al. *J Comp Eff Res.* 2021;10(11):927–938; 5. Rozenbaum MH, et al. *Cardiol Ther.* 2021;10:141–159; 6. Conceição I, et al. *J Peripher Nerv Syst.* 2016;21(1):5–9; 7. Adams D, et al. *J Neurol.* 2021;268:2109–2122; 8. Maurer MS, et al. *Circ Heart Fail.* 2019;12(9):e006075; 9. McDonagh TA, et al. *Eur Heart J.* 2021;42(36):3599–3726; 10. UCL. National Amyloidosis Centre. Available at: <https://www.ucl.ac.uk/medical-sciences/divisions/national-amyloidosis-centre>. Accessed July 2026; 11. UCL. Information for Referring Physicians. Available at: <https://www.ucl.ac.uk/medical-sciences/divisions/national-amyloidosis-centre/information-referring-physicians>. Accessed July 2026.